Orthobiologics Surprise AZ — blood-based shots and joint care

What to notice about the aching

An old injury, years of use, or a tender tendon may cause soreness after chores. Stiffness may follow a long sit, with swelling showing up once you've moved around.

Mark the sore place and note the movement that brings it on. A doctor can use the timing, exact sore spot, and movement that hurts to decide whether the trouble lies in the joint, tendon, or nearby muscle during an exam.

Heat, swelling, and fever together mean you need a doctor before the day ends. Don't wait if the joint locks, looks bent, or won't hold your weight.

What to try before you spend money

Ease back from the chore that starts the ache, but don't stop all movement. Easy daily movement may stop the joint from growing stiffer while it settles.

If extra weight adds strain, slow and steady weight loss may make walking easier. Don't push through a sharp ache just to finish the day's work.

Jot down the chore or movement that brought the soreness on. If home care isn't helping, take that note, an earlier X-ray, and your medicine names to the exam.

What to ask when the soreness doesn't settle

The long word orthobiologics means shots made from body material, usually your own blood. QC Kinetix offers regenerative treatments, meaning non-surgical choices considered after an exam for soreness from joint wear or a tendon problem.

PRP stands for platelet-rich plasma: a small blood draw is spun so platelets collect in one part of the liquid. That part is prepared for the shot.

Concentrated PRP follows those blood-draw and spinning steps, but gathers more platelets into the liquid. A medical provider, the clinician checking you, can explain the limits, cost, and other choices before you decide.

Sources

1. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

2. Medicare's national coverage determination states that CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical study. Every approved study listed under the NCD is a wound-healing study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

3. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

4. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to the more recent orthobiologic-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP ranked LEAST likely; single PRP, multiple PRP and adipose MSC did not produce a relevant reduction in pain or improvement in function versus placebo. The authors noted treatment-effect differences were small and potentially not clinically meaningful either way.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.